Background: There is no current standard of salvage chemotherapy in recurrent OC. Oxaliplatin is an effective third generation platinum compound which has no complete cross-resistance with carboplatin or cisplatin in OC. The purpose of our study was to assess efficacy and tolerability of combination of oxaliplatin and doxorubicin in second-line chemotherapy of OC. Methods: In case of disease progression following first-line chemotherapy pts received second-line chemotherapy with oxaliplatin 130 mg/m² and doxorubicin 50 mg/m² q3w. Time to progression (TTP) was chosen as the primary end-point. Three investigator centers participated in the study. Results: Totally 29 pts were included in this study. Tumors were platinum-sensitive (PFI>12 m) in 5 (17.2%), partially platinum-sensitive (PFI>6 m) in 12 (41.4%), platinum-resistant (PFI<6 m) in 11 (38.0%) cases, in 1 (3.4%) case sensitivity of tumor to platinum was not known. Objective response rate was 55.1% (24.1% complete remissions and 31.0% partial remissions). The median TTP was 10.7 m. With the median f.-up of 14.8 m the median overall survival was not reached. 1-year overall survival was 89%. There were no statistically significant differences in response rate and TTP between platinum-sensitive and platinum-resistant cancers (p>0.05). The median number of cycles was 5 (range 2-6). Toxicity grade 3-4 per cycle included neutropenia 14.6%, febrile neutropenia 0.7%, thrombocytopenia 5.1%. Sensory neuropathy grade 1-2 and 3 was observed in 8 (27.6%) and 2 (1.4%) cases respectively. There were 5 cases of oxaliplatin dose reductions and 10 cases of doxorubicin dose reductions; 10 cycles of chemotherapy were delayed due to toxicity. Conclusions: The combination of oxaliplatin and doxorubicin showed promising efficacy in either platinum-sensitive or platinum-resistant recurrent OC. Tolerability of this regimen was acceptable.